EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study

John F R Robertson iD, Teimuraz Gogitidze, Zaza Katashvili, Juan Enrique Bargalló Rocha, Ekaterine Arkania iD, Iain Moppett iD, Kwok-Leung Cheung iD, Gia Nemsadze, Maxine Ajimi, Teresa Klinowska, Justin P O Lindemann iD, Alastair Mathewson iD und 5 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-25-01548 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von John F R Robertson und 16 weiteren Autor:innen. Beteiligte Einrichtung: University Hospitals of Derby and Burton, Royal Derby Hospital, Derby, United Kingdom. Hauptthemen laut MEDLINE: Azetidines, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Isoquinolines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE SERENA-3 is a presurgical window-of-opportunity (WOO) trial exploring the pharmacodynamic effects of camizestrant in postmenopausal women with newly diagnosed estrogen receptor (ER)–positive, human epidermal growth factor receptor 2–negative breast cancer. METHODS This open-label, parallel-group trial randomly assigned 132 participants to receive camizestrant 75, 150, or 300 mg once daily for 5-7 days or 75 or 150 mg once daily for 12-15 days. The effects of camizestrant on ER expression, activity, and tumor proliferation were assessed in pre- and on-treatment tumor samples by immunohistochemical (IHC) analysis of ER, progesterone receptor (PgR), and Ki67. Exploratory analyses using transcriptomics and mass spectrometry were also performed. RESULTS ER expression was reduced by approximately 65% for all camizestrant doses, regardless of treatment duration. Reduction in Ki67 expression was greater after 12-15 days of camizestrant treatment, compared with 5-7 days. Exploratory analyses including mass spectrometry and IHC image analysis aligned with IHC H-score, indicating equivalent, maximal effects of all tested doses of camizestrant on ER expression and activity and Ki67 expression. Of those participants receiving camizestrant 75 mg once daily, 90%-100% reported no treatment-emergent adverse events across all preferred terms; of those reported, all were Grade 1 except one participant with Grade 2 upper respiratory tract infection, not considered related to camizestrant. CONCLUSION SERENA-3 demonstrates that camizestrant 75 mg once daily (Phase III dose) is well-tolerated and achieves maximal reduction in ER through known mechanisms, that is, antagonism and degradation, by 5-7 days, and proliferation suppression determined by Ki67 expression, by 12-15 days. These data support camizestrant 75 mg once daily as the preferred dose for ongoing clinical development and highlight the importance of presurgical WOO studies in guiding dose selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzetidinesBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesIsoquinolinesReceptors, EstrogenAgedFemaleHumansMiddle AgedCell ProliferationKi-67 AntigenNeoadjuvant TherapyPostmenopauseReceptors, Progesterone

Substanzen

AZD9833AzetidinesErb-b2 Receptor Tyrosine KinasesERBB2 protein, humanIsoquinolinesKi-67 AntigenMKI67 protein, humanReceptors, EstrogenReceptors, Progesterone

Autor:innen und Institutionen

  • University Hospitals of Derby and Burton, Royal Derby Hospital, Derby, United Kingdom.
  • LTD Brothers, Batumi, Ajaria, Georgia.
  • Acad. Fridon Todua Medical Center, Research Institute of Clinical Medicine, Tbilisi, Georgia.
  • Instituto Nacional de Cancerologia (INCAN), Mexico City, Mexico.
  • Helsicore Israeli Georgian Medical Research Clinic, Tbilisi, Georgia.
  • Injury, Recovery and Inflammation Sciences, University of Nottingham, Nottingham, United Kingdom.

ORCID-Profile: John F R Robertson, Ekaterine Arkania, Iain Moppett, Kwok-Leung Cheung, Justin P O Lindemann, Alastair Mathewson, Christopher J Morrow

Zitieren

APA

Robertson, J. F. R., Gogitidze, T., Katashvili, Z., Rocha, J. E. B., Arkania, E., Moppett, I., Cheung, K. L., Nemsadze, G., Ajimi, M., Klinowska, T., Lindemann, J. P. O., Mathewson, A., Morrow, C. J., Nikolaou, M., Scaltriti, M., Sykes, A., & Dzagnidze, G. (2026). Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01548

Vancouver

Robertson JFR, Gogitidze T, Katashvili Z, Rocha JEB, Arkania E, Moppett I, et al. Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-01548

BibTeX
@article{Robertson2026,
  author = {Robertson, John F R and Gogitidze, Teimuraz and Katashvili, Zaza and Rocha, Juan Enrique Bargalló and Arkania, Ekaterine and Moppett, Iain and Cheung, Kwok-Leung and Nemsadze, Gia and Ajimi, Maxine and Klinowska, Teresa and Lindemann, Justin P O and Mathewson, Alastair and Morrow, Christopher J and Nikolaou, Myria and Scaltriti, Maurizio and Sykes, Andy and Dzagnidze, Giorgi},
  title = {Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-25-01548}
}
Kostenlos starten →